Evidence map›Paper›PMID 38180245›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2024

Molecular and Pathologic Characterization of YAP1-Expressing Small Cell Lung Cancer Cell Lines Leads to Reclassification as SMARCA4-Deficient Malignancies.

Jin Ng, Ling Cai, Luc Girard, Owen W J Prall, Neeha Rajan, Christine Khoo, Ahida Batrouney, David J Byrne, Danielle K Boyd, Ariena J Kersbergen and 4 more

Open access · hybridAbstract read
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.

0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed
8.9field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

48 citing papers in PubMed, 59 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. YAP1 Defines an Emergent, Plastic Population of Relapsed SCLC.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2026
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. The Five-Decade Journey of Small Cell Lung Cancer.Cancer communications (London, England) · 2026
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 2 countries.

Jin NgACRF Cancer Biology and Stem Cells Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia.ORCID 0000-0003-0516-7208
Ling CaiQuantitative Biomedical Research Center, Peter O'Donnell Jr. School of Public Health, UT Southwestern Medical Center, Dallas, Texas.ORCID 0000-0002-8592-5269
Luc GirardSimmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, Texas.ORCID 0000-0002-6688-5281
Owen W J PrallDepartment of Anatomical Pathology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.ORCID 0000-0003-1600-5933
Neeha RajanDepartment of Anatomical Pathology, The Royal Melbourne Hospital, Parkville, Victoria, Australia.ORCID 0000-0002-9579-6675
Christine KhooDepartment of Anatomical Pathology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.ORCID 0000-0002-2476-3665
Ahida BatrouneyDepartment of Anatomical Pathology, The Royal Melbourne Hospital, Parkville, Victoria, Australia.ORCID 0009-0002-8800-7057
David J ByrneDepartment of Anatomical Pathology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.ORCID 0000-0002-9258-3252
Danielle K BoydACRF Cancer Biology and Stem Cells Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia.ORCID 0009-0009-5512-5947
Ariena J KersbergenACRF Cancer Biology and Stem Cells Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia.ORCID 0009-0000-5306-0830
Michael ChristieDepartment of Anatomical Pathology, The Royal Melbourne Hospital, Parkville, Victoria, Australia.ORCID 0000-0001-8006-6832
John D MinnaSimmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, Texas.ORCID 0000-0002-7776-0767
Marian L Burr *Division of Genome Science and Cancer, The John Curtin School of Medical Research, The Australian National University, Canberra, Australian Capital Territory, Australia.ORCID 0000-0002-8995-3398
Kate D Sutherland *ACRF Cancer Biology and Stem Cells Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia.ORCID 0000-0002-7453-3366
Peter MacCallum Cancer Centre · AUSouthwestern Medical Center · USThe Royal Melbourne Hospital · AUThe University of Melbourne · AUWalter and Eliza Hall Institute of Medical Research · AUAustralian National University · AU

Funding

UNIVERSITY OF TEXAS--SPORE IN LUNG CANCERP50CA070907 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI HEYMACH, JOHN V., MINNA, JOHN D. · 1996 to 2024
$57.4M
UT Southwestern Medical Center Simmons Comprehensive Cancer CenterP30CA142543 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI MELANIE H. COBB · 2010 to 2026
$53.7M
Coordinating center for the NCI small cell lung cancer research consortiumU24CA213274 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Lauren Averett Byers, JOHN D. MINNA · 2017 to 2026
$12.9M
Developing ASCL1 and NeuroD1 lineage oncogene targeted therapy for small cell lung cancerU01CA213338 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI MINNA, JOHN D. · 2017 to 2021
$3.0M
AOU NIH HHS CA213274AOU NIH HHS CA213338AOU NIH HHS P50 CA070907NCI NIH HHS P30 CA142543NCI NIH HHS P50 CA070907NCI NIH HHS U01 CA213338NCI NIH HHS U24 CA213274
6 · The paper itself

Abstract

purposeThe classification of small cell lung cancer (SCLC) into distinct molecular subtypes defined by ASCL1, NEUROD1, POU2F3, or YAP1 (SCLC-A, -N, -P, or -Y) expression, paves the way for a personalized treatment approach. However, the existence of a distinct YAP1-expressing SCLC subtype remains controversial. EXPERIMENTAL

designTo better understand YAP1-expressing SCLC, the mutational landscape of human SCLC cell lines was interrogated to identify pathogenic alterations unique to SCLC-Y. Xenograft tumors, generated from cell lines representing the four SCLC molecular subtypes, were evaluated by a panel of pathologists who routinely diagnose thoracic malignancies. Diagnoses were complemented by transcriptomic analysis of primary tumors and human cell line datasets. Protein expression profiles were validated in patient tumor tissue.

resultsUnexpectedly, pathogenic mutations in SMARCA4 were identified in six of eight SCLC-Y cell lines and correlated with reduced SMARCA4 mRNA and protein expression. Pathologist evaluations revealed that SMARCA4-deficient SCLC-Y tumors exhibited features consistent with thoracic SMARCA4-deficient undifferentiated tumors (SMARCA4-UT). Similarly, the transcriptional profile SMARCA4-mutant SCLC-Y lines more closely resembled primary SMARCA4-UT, or SMARCA4-deficient non-small cell carcinoma, than SCLC. Furthermore, SMARCA4-UT patient samples were associated with a YAP1 transcriptional signature and exhibited strong YAP1 protein expression. Together, we found little evidence to support a diagnosis of SCLC for any of the YAP1-expressing cell lines originally used to define the SCLC-Y subtype.

conclusionsSMARCA4-mutant SCLC-Y cell lines exhibit characteristics consistent with SMARCA4-deficient malignancies rather than SCLC. Our findings suggest that, unlike ASCL1, NEUROD1, and POU2F3, YAP1 is not a subtype defining transcription factor in SCLC. See related commentary by Rekhtman, p. 1708.

Indexed as

Adaptor Proteins, Signal TransducingDNA HelicasesLung NeoplasmsMutationNuclear ProteinsSmall Cell Lung CarcinomaTranscription FactorsYAP-Signaling ProteinsAnimalsBiomarkers, TumorCell Line, TumorGene Expression ProfilingGene Expression Regulation, NeoplasticHumansMicePhosphoproteinsAdaptor Proteins, Signal TransducingBiomarkers, TumorDNA HelicasesNuclear ProteinsPhosphoproteinsSMARCA4 protein, humanTranscription FactorsYAP1 protein, humanYAP-Signaling Proteins

Identifiers

PMID38180245
PMCPMC11061608
OpenAlexW4390617747

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.